Filed with ASX · · 4 pages · English
This filing is an announcement of the Chairman's address at the Annual General Meeting of Algorae Pharmaceuticals Limited, detailing the company's progress and future outlook. The Chairman highlighted significant commercial partnerships and advancements in their AI drug discovery platform, AlgoraeOS, which has shown promising results in identifying drug combinations. The address also covered the company's financial position, including recent funding and capital management strategies to support growth and product commercialization. Looking ahead, the Chairman emphasized key milestones, including product registrations and supply agreements, as well as the importance of execution in achieving revenue goals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT ASX: 1AI | 5 November 2026 Annual General Meeting: Chairman's Address to Shareholders Melbourne, Australia, 5 November 2026: Algorae Pharmaceuticals Limited ('Algorae' or 'the Company') (ASX code: 1AI) is pleased to enclose the address of the Chairman at the Annual General Meeting...
Algorae Pharmaceuticals Limited on 6ix
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals